Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma.
Cancer Diagn Progn
; 3(3): 370-376, 2023.
Article
in En
| MEDLINE
| ID: mdl-37168961